Advanced Accelerator Applications (AAA) announced on March 23, 2016 that the company has initiated an expanded access program (EAP) in the United States for the investigational product, Lutathera. Through the program Lutathera is being made available to patients with “inoperable, somatostatin receptor positive, midgut carcinoid tumors, progressive under somatostatin analogue therapy.” Read more at www.clinicaltrials.gov (trial number NCT02705313). And more exciting news: AAA announced a New Drug Application (NDA) filing plan for Lutathera to the U.S. Food and Drug Administration (FDA). Download the press release and read more here: http://www.adacap.com/press-room/.
To learn more about Peptide Receptor Radionuclide Therapy, PRRT, watch the video below.
